Tybost Dosage
Generic name: COBICISTAT 150mg
Dosage form: tablet, film coated
Drug class: Antiviral boosters
Medically reviewed by Drugs.com. Last updated on Jun 20, 2025.
Recommended Dosage in Adults
Administer TYBOST in conjunction with atazanavir or darunavir and other antiretroviral agents in the treatment of adults with HIV-1 infection. The recommended dosages of TYBOST and atazanavir or darunavir given with food are presented in Table 1. TYBOST must be coadministered at the same time as atazanavir or darunavir. Consult the prescribing information for atazanavir or darunavir.
| Patient Populations | Coadministered Agent Dosage | TYBOST Dosage |
|---|---|---|
| Treatment-naïve or treatment-experienced | atazanavir 300 mg orally once daily | 150 mg orally once daily |
| Treatment-naïve or treatment-experienced with no darunavir resistance-associated substitutions | darunavir 800 mg orally once daily |
Recommended Dosage in Pediatric Patients
Administer TYBOST in conjunction with atazanavir or darunavir and other antiretroviral agents in the treatment of pediatric patients with HIV-1 infection. The recommended dosages of TYBOST and atazanavir or darunavir given with food are based on weight and presented in Table 2 and Table 3, respectively. TYBOST must be coadministered at the same time as atazanavir or darunavir. Consult the prescribing information for atazanavir or darunavir.
| Body Weight | Atazanavir Dosage | TYBOST Dosage |
|---|---|---|
| Weighing at least 14 kg to less than 25 kg | 200 mg orally once daily | 90 mg orally once daily |
| Weighing at least 25 kg to less than 35 kg | 200 mg orally once daily | 150 mg orally once daily |
| Weighing at least 35 kg | 300 mg orally once daily |
| Body Weight | Darunavir Dosage | TYBOST Dosage |
|---|---|---|
| Weighing at least 15 kg to less than 25 kg | 600 mg orally once daily | 90 mg orally once daily |
| Weighing at least 25 kg to less than 30 kg | 600 mg orally once daily | 150 mg orally once daily |
| Weighing at least 30 kg to less than 40 kg | 675 mg orally once daily | |
| Weighing at least 40 kg | 800 mg orally once daily |
Testing Prior to Initiation of TYBOST
Prior to or when initiating TYBOST and during treatment with TYBOST, on a clinically appropriate schedule, assess estimated creatinine clearance because TYBOST decreases estimated creatinine clearance due to inhibition of tubular secretion of creatinine without affecting actual renal glomerular function. When coadministering TYBOST with TDF, assess estimated creatinine clearance, urine glucose, and urine protein at baseline. In patients with chronic kidney disease, also assess serum phosphorus.
Renal Impairment
TYBOST coadministered with TDF is not recommended in patients who have an estimated creatinine clearance below 70 mL/min because dose adjustment of TDF is required below 50 mL/min and such dose adjustments have not been established for coadministration with TYBOST.
Not Recommended During Pregnancy
TYBOST coadministered with darunavir is not recommended for use during pregnancy because of substantially lower exposures of darunavir and cobicistat during the second and third trimesters.
TYBOST coadministered with atazanavir is not recommended for use during pregnancy because of substantially lower exposures of cobicistat during the second and third trimesters.
TYBOST coadministered with darunavir or atazanavir should not be initiated in pregnant individuals. An alternative regimen is recommended for individuals who become pregnant during therapy with TYBOST coadministered with darunavir or atazanavir.
Frequently asked questions
- What drugs are contained in the HIV treatment Symtuza?
- Genvoya vs Stribild for HIV - How do they compare?
More about Tybost (cobicistat)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- During pregnancy
- FDA approval history
- Drug class: antiviral boosters
- En español
Patient resources
Professional resources
Related treatment guides
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
